“Our study, which included adults and children with advanced, solid tumors that could not be surgically removed, showed promising activity against V600 and non-V600 BRAF mutant tumors, including primary central nervous system (CNS) tumors,” said Dr. Macarena de la Fuente, chief of Neuro-Oncology at Sylvester Comprehensive Cancer Center, whose research focuses on developing treatments for primary brain tumors. Photo courtesy of Sylvester.